DE69114299D1 - Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems. - Google Patents
Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.Info
- Publication number
- DE69114299D1 DE69114299D1 DE69114299T DE69114299T DE69114299D1 DE 69114299 D1 DE69114299 D1 DE 69114299D1 DE 69114299 T DE69114299 T DE 69114299T DE 69114299 T DE69114299 T DE 69114299T DE 69114299 D1 DE69114299 D1 DE 69114299D1
- Authority
- DE
- Germany
- Prior art keywords
- polypeptide
- gene encoding
- promoter
- exogenous gene
- lethal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58271190A | 1990-09-14 | 1990-09-14 | |
US582711 | 1990-09-14 | ||
PCT/US1991/006612 WO1992005262A1 (en) | 1990-09-14 | 1991-09-12 | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69114299D1 true DE69114299D1 (de) | 1995-12-07 |
DE69114299T2 DE69114299T2 (de) | 1996-06-27 |
DE69114299T3 DE69114299T3 (de) | 2005-09-15 |
Family
ID=24330225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69114299T Expired - Lifetime DE69114299T3 (de) | 1990-09-14 | 1991-09-12 | Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0551401B2 (de) |
JP (3) | JPH06501161A (de) |
AT (1) | ATE129746T1 (de) |
AU (1) | AU3041295A (de) |
CA (1) | CA2091346C (de) |
DE (1) | DE69114299T3 (de) |
DK (1) | DK0551401T3 (de) |
ES (1) | ES2080341T3 (de) |
GR (1) | GR3018897T3 (de) |
WO (1) | WO1992005262A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2080341T3 (es) * | 1990-09-14 | 1996-02-01 | Univ Johns Hopkins | Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral. |
US5681562A (en) * | 1991-06-25 | 1997-10-28 | Sidney Kimmel Cancer Center | Lymphokine gene therapy of cancer |
WO1993002556A1 (en) * | 1991-07-26 | 1993-02-18 | University Of Rochester | Cancer therapy utilizing malignant cells |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
WO1993006867A1 (en) * | 1991-10-04 | 1993-04-15 | Whitehead Institute For Biomedical Research | The regulation of systemic immune responses utilizing cytokines and antigens |
IL99821A (en) * | 1991-10-22 | 1996-07-23 | Yeda Res & Dev | Antitumor vaccines comprising cells transfected with a gene encoding human il-6 |
CA2121127A1 (en) * | 1991-10-25 | 1993-04-29 | Robert E. Sobol | Lymphokine gene therapy of cancer |
FR2683725B1 (fr) * | 1991-11-15 | 1995-07-07 | Pasteur Institut | Composition cellulaire pour le traitement des organismes humains ou animaux. |
WO1993021959A1 (en) * | 1992-05-01 | 1993-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bystander effect tumoricidal therapy |
US5902576A (en) * | 1992-10-22 | 1999-05-11 | Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science | Antitumor pharmaceutical composition comprising IL-6 transfected cells |
DE69433110T2 (de) * | 1993-02-17 | 2004-06-03 | Sloan-Kettering Institute For Cancer Research | Allogenes vakzin und synthesemethode für selbiges |
AU729199B2 (en) * | 1993-02-22 | 2001-01-25 | Assistance Publique - Hopitaux De Paris | Composition for use in the treatment of tumours and the immunization of humans and animals |
FR2699082B1 (fr) * | 1993-02-22 | 1995-05-05 | Pasteur Institut | Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs. |
US5645829A (en) * | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
IT1261847B (it) * | 1993-09-01 | 1996-06-03 | San Romanello Centro Fond | Metodo per marcare cellule eucariote. |
JPH09504518A (ja) * | 1993-10-06 | 1997-05-06 | アメリカ合衆国 | 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療 |
FR2712602B1 (fr) * | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
FR2712603B1 (fr) * | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
DE69535288T2 (de) * | 1994-05-13 | 2007-04-05 | Thomas Jefferson University | Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren |
ES2186686T3 (es) * | 1994-05-16 | 2003-05-16 | Roche Diagnostics Gmbh | Metodo de inmunomodulacion por medio de transferencia adoptiva de linfocitos t-citotoxicos especificos de antigenos. |
DE4418965A1 (de) * | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen |
CA2156132A1 (en) * | 1994-08-16 | 1996-02-17 | Abraham Bout | Recombinant vectors derived from adenovirus for use in gene therapy |
WO1996013275A1 (en) * | 1994-10-31 | 1996-05-09 | Tkb Associates Limited Partnership | Methods and products for enhancing immune responses |
DE19510344C1 (de) * | 1995-03-22 | 1996-11-07 | Boehringer Ingelheim Int | Verwendung einer Tumorvakzine |
US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
ATE237338T1 (de) * | 1995-12-28 | 2003-05-15 | Univ Johns Hopkins Med | Allogene parakrine cytokine tumor impfstoffe |
US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
US6268214B1 (en) | 1996-04-04 | 2001-07-31 | Roche Diagnostics Gmbh | Vectors encoding a modified low affinity nerve growth factor receptor |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
ATE283069T1 (de) | 1996-08-16 | 2004-12-15 | Univ Johns Hopkins Med | Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung |
US6087174A (en) * | 1996-12-26 | 2000-07-11 | Johns Hopkins University, School Of Medicine | Growth medium for primary pancreatic tumor cell culture |
ES2232845T3 (es) * | 1997-08-22 | 2005-06-01 | Science Park Raf S.P.A. | Vacunacion tumoral mediante la utilizacion de celulas autologas o celulas presentadoras de antigeno (apc) relacionadas con hla transducidas con un antigeno tumoral y un antigeno ajeno capaz de producir una reaccion inmune. |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US8425897B2 (en) | 2007-08-30 | 2013-04-23 | Immutep S.A. | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use |
US9907582B1 (en) | 2011-04-25 | 2018-03-06 | Nuvasive, Inc. | Minimally invasive spinal fixation system and related methods |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2080341T3 (es) * | 1990-09-14 | 1996-02-01 | Univ Johns Hopkins | Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral. |
-
1991
- 1991-09-12 ES ES91918778T patent/ES2080341T3/es not_active Expired - Lifetime
- 1991-09-12 WO PCT/US1991/006612 patent/WO1992005262A1/en active IP Right Grant
- 1991-09-12 DK DK91918778.1T patent/DK0551401T3/da active
- 1991-09-12 CA CA002091346A patent/CA2091346C/en not_active Expired - Lifetime
- 1991-09-12 DE DE69114299T patent/DE69114299T3/de not_active Expired - Lifetime
- 1991-09-12 EP EP91918778A patent/EP0551401B2/de not_active Expired - Lifetime
- 1991-09-12 JP JP3517865A patent/JPH06501161A/ja not_active Withdrawn
- 1991-09-12 AT AT91918778T patent/ATE129746T1/de not_active IP Right Cessation
-
1995
- 1995-09-01 AU AU30412/95A patent/AU3041295A/en not_active Abandoned
-
1996
- 1996-02-01 GR GR960400294T patent/GR3018897T3/el unknown
-
2007
- 2007-07-19 JP JP2007188896A patent/JP2007277265A/ja not_active Withdrawn
-
2009
- 2009-04-23 JP JP2009105739A patent/JP2009165490A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69114299T2 (de) | 1996-06-27 |
JPH06501161A (ja) | 1994-02-10 |
ATE129746T1 (de) | 1995-11-15 |
WO1992005262A1 (en) | 1992-04-02 |
EP0551401A1 (de) | 1993-07-21 |
GR3018897T3 (en) | 1996-05-31 |
JP2009165490A (ja) | 2009-07-30 |
JP2007277265A (ja) | 2007-10-25 |
DK0551401T3 (da) | 1996-01-22 |
CA2091346A1 (en) | 1992-03-15 |
AU659812B2 (en) | 1995-06-01 |
ES2080341T3 (es) | 1996-02-01 |
DE69114299T3 (de) | 2005-09-15 |
EP0551401B1 (de) | 1995-11-02 |
AU8764391A (en) | 1992-04-15 |
CA2091346C (en) | 2007-04-24 |
EP0551401B2 (de) | 2004-12-01 |
AU3041295A (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69114299D1 (de) | Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems. | |
JP3195958B2 (ja) | 悪性腫瘍の治療又は予防のための医薬組成物 | |
DE68929507D1 (de) | Rekombinante mykobakterielle expressions-träger sowie deren verwendung | |
Schultz et al. | Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA | |
ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
AU675948B2 (en) | Bystander effect tumoricidal therapy | |
EA002688B1 (ru) | Способы инактивации клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, используемые для получения этих агентов | |
WO2003023000A3 (en) | Linear dna fragments for gene expression | |
AU5848090A (en) | Vector-mediated genomic insertion and expression of dna in bcg | |
WO2003042362A3 (en) | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR | |
Delman et al. | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer | |
DK0781344T3 (da) | Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme | |
PL332568A1 (en) | Region of human stature size control gene and small stature gene | |
AU2002320301A1 (en) | Novel pgc-1 isoforms and uses therefor | |
HUP9802587A2 (hu) | Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek | |
US6090378A (en) | Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors | |
Yeung et al. | Production of rabbit polyclonal antibody against apobec-1 by genetic immunization | |
ATE197609T1 (de) | Verfahren zur unterdrückung der immunantwort durch gentherapie | |
KR100399728B1 (ko) | IL-12 활성을 증가시키는 IL-12p40 소단위체돌연변이 유전자 및 이를 DNA 백신 면역증강제로이용하는 용도 | |
Lu et al. | Retinoblastoma protein regulation of surface CD74 (invariant chain) expression in breast carcinoma cells | |
WO2002018556A3 (en) | 8797, a human galactosyltransferase and uses thereof | |
WO2001068857A3 (en) | 18615 and 48003, human ion channels and uses therefor | |
WO2002010391A3 (en) | 18610, a human transient receptor and uses thereof | |
WO1994021118A1 (en) | Gene-therapy composition and method for treating carcinomas | |
AU2001253258A1 (en) | Human trp-like calcium channel protein-2 (tlcc-2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER WICHMANN HU |